LGVN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LGVN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Longeveron's enterprise value is $7.37 Mil. Longeveron's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.71 Mil. Therefore, Longeveron's EV-to-Revenue for today is 10.40.
The historical rank and industry rank for Longeveron's EV-to-Revenue or its related term are showing as below:
During the past 6 years, the highest EV-to-Revenue of Longeveron was 250.71. The lowest was 0.95. And the median was 47.38.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-05-08), Longeveron's stock price is $1.66. Longeveron's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.33. Therefore, Longeveron's PS Ratio for today is 4.97.
The historical data trend for Longeveron's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longeveron Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
EV-to-Revenue | Get a 7-Day Free Trial | - | - | 168.53 | 41.43 | 43.48 |
Longeveron Quarterly Data | |||||||||||||||||||
Dec18 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-Revenue | Get a 7-Day Free Trial | 41.43 | 39.74 | 73.95 | 62.74 | 43.48 |
For the Biotechnology subindustry, Longeveron's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Longeveron's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Longeveron's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Longeveron's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 7.372 | / | 0.709 | |
= | 10.40 |
Longeveron's current Enterprise Value is $7.37 Mil.
Longeveron's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longeveron (NAS:LGVN) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Longeveron's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 1.66 | / | 0.334 | |
= | 4.97 |
Longeveron's share price for today is $1.66.
Longeveron's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Longeveron's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Cathy Ross | director | 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136 |
Khoso Baluch | director | 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921 |
Jeffrey Pfeffer | director | |
Lisa Locklear | officer: Chief Financial Officer | 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136 |
Nataliya Agafonova | officer: Chief Medical Officer | 1951 NW 7TH AVENUE, MIAMI FL 33136 |
James Clavijo | officer: CFO and Treasurer | 1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139 |
Hashad Mohamed Wa'el Ahmed | officer: Chief Executive Officer | SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136 |
Joshua Hare | director, officer: Chief Scientific Officer | C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073 |
Rock Soffer | director | 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136 |
Kwan-hong Christopher Min | officer: Chief Medical Officer | 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136 |
Todd C Girolamo | director | 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920 |
Geoff Green | officer: CEO | 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136 |
Paul T Lehr | officer: General Counsel, Secretary | 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136 |
Ursula Ungaro | director | 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136 |
Donald M Soffer | director, 10 percent owner | 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136 |
From GuruFocus
By Marketwired • 08-14-2023
By Marketwired • 08-22-2023
By Marketwired • 11-03-2023
By sperokesalga sperokesalga • 02-28-2023
By Marketwired • 09-07-2023
By Marketwired • 10-12-2023
By Marketwired • 07-11-2023
By Stock market mentor Stock market mentor • 01-19-2023
By Marketwired • 08-14-2023
By sperokesalga sperokesalga • 04-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.